These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 25688114)

  • 1. Therogenetics: transferring GWAS technology to the clinic.
    Cox DG; Heudel PE; Trédan O; Bachelot T
    Mutagenesis; 2015 Mar; 30(2):213-5. PubMed ID: 25688114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome-wide association studies and the clinic: a focus on breast cancer.
    Véron A; Blein S; Cox DG
    Biomark Med; 2014; 8(2):287-96. PubMed ID: 24521025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using tumour pathology to identify people at high genetic risk of breast and colorectal cancers.
    Hopper JL; Jenkins MA; Dowty JG; Dite GS; Apicella C; Keogh L; Win AK; Young JP; Buchanan D; Walsh MD; Rosty C; Baglietto L; Severi G; Phillips KA; Wong EM; Dobrovic A; Waring P; Winship I; Ramus SJ; Giles GG; Southey MC
    Pathology; 2012 Feb; 44(2):89-98. PubMed ID: 22198256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of germline variants in the metastasis of breast carcinomas.
    Santonja Á; Moya-García AA; Ribelles N; Jiménez-Rodríguez B; Pajares B; Fernández-De Sousa CE; Pérez-Ruiz E; Del Monte-Millán M; Ruiz-Borrego M; de la Haba J; Sánchez-Rovira P; Romero A; González-Neira A; Lluch A; Alba E
    Oncotarget; 2022; 13():843-862. PubMed ID: 35782051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families.
    Durocher F; Labrie Y; Soucy P; Sinilnikova O; Labuda D; Bessette P; Chiquette J; Laframboise R; Lépine J; Lespérance B; Ouellette G; Pichette R; Plante M; Tavtigian SV; Simard J
    BMC Cancer; 2006 Sep; 6():230. PubMed ID: 17010193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis.
    Escala-Garcia M; Canisius S; Keeman R; Beesley J; Anton-Culver H; Arndt V; Augustinsson A; Becher H; Beckmann MW; Behrens S; Bermisheva M; Bojesen SE; Bolla MK; Brenner H; Canzian F; Castelao JE; Chang-Claude J; Chanock SJ; Couch FJ; Czene K; Daly MB; Dennis J; Devilee P; Dörk T; Dunning AM; Easton DF; Ekici AB; Eliassen AH; Fasching PA; Flyger H; Gago-Dominguez M; García-Closas M; García-Sáenz JA; Geisler J; Giles GG; Grip M; Gündert M; Hahnen E; Haiman CA; Håkansson N; Hall P; Hamann U; Hartikainen JM; Heemskerk-Gerritsen BAM; Hollestelle A; Hoppe R; Hopper JL; Hunter DJ; Jacot W; Jakubowska A; John EM; Jung AY; Kaaks R; Khusnutdinova E; Koppert LB; Kraft P; Kristensen VN; Kurian AW; Lambrechts D; Le Marchand L; Lindblom A; Luben RN; Lubiński J; Mannermaa A; Manoochehri M; Margolin S; Mavroudis D; Muranen TA; Nevanlinna H; Olshan AF; Olsson H; Park-Simon TW; Patel AV; Peterlongo P; Pharoah PDP; Punie K; Radice P; Rennert G; Rennert HS; Romero A; Roylance R; Rüdiger T; Ruebner M; Saloustros E; Sawyer EJ; Schmutzler RK; Schoemaker MJ; Scott C; Southey MC; Surowy H; Swerdlow AJ; Tamimi RM; Teras LR; Thomas E; Tomlinson I; Troester MA; Vachon CM; Wang Q; Winqvist R; Wolk A; Ziogas A; ; Michailidou K; Chenevix-Trench G; Bachelot T; Schmidt MK
    Sci Rep; 2021 Oct; 11(1):19787. PubMed ID: 34611289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant.
    de Bock GH; Schutte M; Krol-Warmerdam EM; Seynaeve C; Blom J; Brekelmans CT; Meijers-Heijboer H; van Asperen CJ; Cornelisse CJ; Devilee P; Tollenaar RA; Klijn JG
    J Med Genet; 2004 Oct; 41(10):731-5. PubMed ID: 15466005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate cancer: germline prediction for a commonly variable malignancy.
    Bambury RM; Gallagher DJ
    BJU Int; 2012 Dec; 110(11 Pt C):E809-18. PubMed ID: 22974436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH.
    Joosse SA; van Beers EH; Tielen IH; Horlings H; Peterse JL; Hoogerbrugge N; Ligtenberg MJ; Wessels LF; Axwijk P; Verhoef S; Hogervorst FB; Nederlof PM
    Breast Cancer Res Treat; 2009 Aug; 116(3):479-89. PubMed ID: 18704682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.
    Kuschel B; Lux MP; Goecke TO; Beckmann MW
    Eur J Cancer Prev; 2000 Jun; 9(3):139-50. PubMed ID: 10954253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations.
    Fackenthal JD; Olopade OI
    Nat Rev Cancer; 2007 Dec; 7(12):937-48. PubMed ID: 18034184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCA1: the enigma of tissue-specific tumor development.
    Monteiro AN
    Trends Genet; 2003 Jun; 19(6):312-5. PubMed ID: 12801723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic risk of breast cancer.
    Nasir A; Shackelford RE; Anwar F; Yeatman TJ
    Minerva Endocrinol; 2009 Dec; 34(4):295-309. PubMed ID: 20046159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and pathological features of BRCA1 associated carcinomas in a hospital-based sample of Dutch breast cancer patients.
    de Bock GH; Tollenaar RA; Papelard H; Cornelisse CJ; Devilee P; van de Vijver MJ
    Br J Cancer; 2001 Nov; 85(9):1347-50. PubMed ID: 11720473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PALB2 germline mutations in familial breast cancer cases with personal and family history of pancreatic cancer.
    Peterlongo P; Catucci I; Pasquini G; Verderio P; Peissel B; Barile M; Varesco L; Riboni M; Fortuzzi S; Manoukian S; Radice P
    Breast Cancer Res Treat; 2011 Apr; 126(3):825-8. PubMed ID: 21184274
    [No Abstract]   [Full Text] [Related]  

  • 16. No germline FH mutations in familial breast cancer patients.
    Kiuru M; Lehtonen R; Eerola H; Aittomäki K; Blomqvist C; Nevanlinna H; Aaltonen LA; Launonen V
    Eur J Hum Genet; 2005 Apr; 13(4):506-9. PubMed ID: 15523491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic counseling and management of newly diagnosed breast cancer patients at genetic risk for BRCA germline mutations.
    Silva E; Lynch H
    Breast J; 2006; 12(3):280-1; author reply 282-4. PubMed ID: 16684334
    [No Abstract]   [Full Text] [Related]  

  • 18. Hereditary breast/ovarian cancer: clinicopathological characteristics and survival of BRCA2 positive and negative cases.
    Syamala V; Syamala VS; Sreeja L; Raveendran PB; Vijayalekshmi RV; Sheeja VR; Santhi S; Kuttan R; Abraham EK; Ankathil R
    J Exp Ther Oncol; 2008; 7(3):227-36. PubMed ID: 19066131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
    Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
    Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast cancer genetics: what we know and what we need.
    Nathanson KL; Wooster R; Weber BL
    Nat Med; 2001 May; 7(5):552-6. PubMed ID: 11329055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.